首页> 外文期刊>BMC Health Services Research >Identifying and explaining the variability in development and implementation costs of disease management programs in the Netherlands
【24h】

Identifying and explaining the variability in development and implementation costs of disease management programs in the Netherlands

机译:识别并解释荷兰疾病管理计划的开发和实施成本的可变性

获取原文
           

摘要

Background In the Netherlands, disease management programs (DMPs) are used to treat chronic diseases. Their aim is to improve care and to control the rising expenditures related to chronic diseases. A bundled payment was introduced to facilitate the implementation of DMPs. This payment is an all-inclusive price per patient per year for a pre-specified care package. However, it is unclear to which extent the costs of developing and implementing DMPs are included in this price. Consequently, the organizations providing DMPs bear financial risk because the development and implementation (D&I) costs may be substantial. The aim of this paper is to investigate the variability in and drivers of D&I costs among 22 DMPs and highlight characteristics that impact these. Methods The data was analyzed using a mixed methods approach. Descriptive statistical analysis explored the variability in D&I costs as measured by a self-developed costing instrument and investigated the drivers. In addition, qualitative research, including document analysis and interviews, was conducted to explain the possible underlying reasons of cost variability. Results The development costs varied from €5,891 to €274,783 and the implementation costs varied from €7,278 to €387,879 across DMPs. Personnel costs were the main component of development. Development costs were strongly correlated with the implementation costs (ρ = 0.55), development duration (ρ = 0.74), and number of FTEs dedicated DMP development. Organizations with large size and high level of care prior to the implementation of a DMP had relatively low development costs. These findings were in line with the cross-case qualitative comparison where programs with a longer history, more experienced project leadership, previously established ICT systems, and less complex patient populations had lower D&I costs. Conclusions There is wide variation in D&I costs of DMPs, which is driven primarily by the duration of the development phase and the staff needed to develop and implement a DMP. These drivers are influenced by the attributes of the DMP, characteristics of the target population, project leadership, and ICT involved. There are indications of economies of scale and economies of scope, which may reduce D&I costs.
机译:背景技术在荷兰,疾病管理计划(DMP)用于治疗慢性疾病。他们的目标是改善护理并控制与慢性病有关的不断增加的支出。引入捆绑付款以促进DMP的实施。对于预先指定的护理套餐,此付款是每位患者每年的全包价格。但是,尚不清楚该价格中将开发和实施DMP的成本包括在何种程度上。因此,提供DMP的组织要承担财务风险,因为开发和实施(D&I)成本可能很大。本文的目的是调查22个DMP中D&I成本的变化和动因,并重点介绍影响这些DMP的特征。方法采用混合方法对数据进行分析。描述性统计分析探索了由自行开发的成本核算工具衡量的D&I成本的可变性,并调查了驱动因素。此外,还进行了定性研究,包括文件分析和访谈,以解释成本变化的可能潜在原因。结果整个DMP的开发费用从5,891欧元到274,783欧元不等,实施成本从7,278欧元到387,879欧元不等。人事费用是发展的主要组成部分。开发成本与实施成本(ρ= 0.55),开发持续时间(ρ= 0.74)和FTE专用DMP开发的数量密切相关。在实施DMP之前规模大,护理水平高的组织具有相对较低的开发成本。这些发现与跨案例的定性比较是一致的,在该定性比较中,具有较长历史,经验丰富的项目领导,以前建立的ICT系统以及较不复杂的患者群体的项目的D&I成本较低。结论DMP的D&I成本差异很大,这主要受开发阶段的持续时间以及开发和实施DMP所需的人员的驱动。这些驱动因素受DMP的属性,目标人群的特征,项目领导和涉及的ICT的影响。有迹象表明规模经济和范围经济可以减少D&I成本。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号